Caprock Group LLC Raises Position in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Caprock Group LLC boosted its holdings in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 280.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 58,563 shares of the company's stock after purchasing an additional 43,165 shares during the period. Caprock Group LLC's holdings in Dr. Reddy's Laboratories were worth $925,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. lifted its stake in shares of Dr. Reddy's Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock valued at $180,620,000 after acquiring an additional 9,373,412 shares during the last quarter. World Investment Advisors LLC bought a new position in shares of Dr. Reddy's Laboratories in the 3rd quarter valued at $3,459,000. Crossmark Global Holdings Inc. lifted its stake in shares of Dr. Reddy's Laboratories by 328.3% in the 4th quarter. Crossmark Global Holdings Inc. now owns 12,760 shares of the company's stock valued at $201,000 after acquiring an additional 9,781 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of Dr. Reddy's Laboratories by 441.8% in the 4th quarter. Nordea Investment Management AB now owns 125,363 shares of the company's stock valued at $1,992,000 after acquiring an additional 102,226 shares during the last quarter. Finally, Atomi Financial Group Inc. bought a new position in shares of Dr. Reddy's Laboratories in the 4th quarter valued at $162,000. 3.85% of the stock is currently owned by institutional investors.

Dr. Reddy's Laboratories Stock Up 1.8 %

NYSE RDY traded up $0.25 during trading hours on Tuesday, hitting $13.86. The company's stock had a trading volume of 1,460,430 shares, compared to its average volume of 2,067,747. Dr. Reddy's Laboratories Limited has a 52 week low of $13.36 and a 52 week high of $16.89. The company has a market capitalization of $11.57 billion, a PE ratio of 22.07 and a beta of 0.50. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company's 50-day simple moving average is $14.80 and its two-hundred day simple moving average is $15.43.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. Research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on RDY. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th. Barclays decreased their price objective on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a report on Wednesday, November 6th. Finally, StockNews.com downgraded Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th.

Dr. Reddy's Laboratories Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.